News

Honoring outstanding postdoctoral scientists from academic research institutions across New York, New Jersey, and Connecticut, the Blavatnik Family Foundation and the New York Academy of Sciences announced the three Winners and six Finalists of the 2021 Blavatnik Regional Awards for Young Scientists. 

Biologists aspire to understand every gene’s contribution to an organism’s biology and behavior. Microbiologist Wenyan Jiang has helped repurpose the CRISPR-Cas system, an immune system of many bacteria, and co-opt it to upgrade the way many scientists control and examine the genome. Jiang developed a groundbreaking tool called CRISPR Adaptation-mediated Library Manufacturing (CALM), which exploits CRISPR RNA, a type of RNA naturally found in bacteria. CALM has enabled scientists to quickly determine the causal link between genes and bacterial behaviors such as antibiotic resistance and pathogenesis and pave the way for developing new, effective antimicrobial drugs. 

Read full article on Blavatnik Award site

September 10, 2021

New award for Harris Wang

Harris Wang receives the Vilcek Prize for Creative Promise in Biomedical Science for the development and application of Multiplex Automated Genome Engineering (MAGE), a new framework for manipulating DNA to produce synthetic or engineered recombinant genetic material, and for his use of CRISPR technology to track and record transient cellular processes in the human gut microbiome. Born in Beijing, China, Wang is an associate professor at Columbia University in New York.

The 2022 Vilcek Foundation Prizes in Biomedical Science are a part of the Vilcek Foundation Prizes program. In 2022, the foundation is awarding the Vilcek Foundation Prizes in Biomedical Science, the Vilcek Foundation Prizes in Dance, and the Vilcek Prize for Excellence.

See full article on Vilcek Foundation site.

September 7, 2021

New award for Tal Korem

Tal Korem, PhD, Systems Biology and Obstetrics & Gynecology, will receive $3,404,285 over five years from the Eunice Kennedy Shriver National Institute of Child Health and Human Development for "A large scale investigation of the vaginal metagenome and metabolome and their role in spontaneous preterm birth”.
 
This award will support the efforts of the Korem lab, along with Co-Investigators Dr. Anne-Catrin Uhlemann (Department of Medicine) and Dr. Ronald Wapner (Department of Obstetrics & Gynecology), to understand the role of the vaginal microbiome in preterm birth, the leading cause of neonatal morbidity and mortality. The investigators will generate a dataset of paired vaginal microbiome and metabolome measurements from samples collected along pregnancy in a large prospective cohort. Using this data, they will seek to identify new biomarkers for early identification of preterm birth and investigate the metabolic mechanisms that potentially underly it. 

Barry Honig, PhD, Systems Biology, will receive $2,025,000 over four years from the National Institute of General Medical Sciences for “Genome-Wide Structure-Based Analysis of Protein-Protein Interactions and Networks.”

Read full article in CUIMC Newsroom.

Three early-career scientists at VP&S—X. Shawn Liu (Physiology & Cellular Biophysics), Xuebing Wu(link is external and opens in a new window) (Medicine), and Nikhil Sharma (Molecular Pharmacology & Therapeutics)—have been selected as 2021 Paul A. Marks Scholars.

Established in 2006, the Paul A. Marks Scholars Program honors the extraordinary legacy of the late Paul A. Marks, MD’49(link is external and opens in a new window), by supporting the recruitment and retention of outstanding early career scientists with a primary tenure-track assistant professor appointment in one of the basic science departments at Columbia University Vagelos College of Physicians and Surgeons. The program funds up to three scientists at $100,000 per year for a period of three years.

Marks, who died in 2020, was an internationally renowned physician-scientist and an exceptional academic leader. Marks served as VP&S dean from 1970 to 1973 and vice president for medical sciences at VP&S from 1973 to 1980 before serving as president and CEO of Memorial Sloan Kettering Cancer Center from 1980 to 1999.

Through his pioneering investigations in cancer biology and genetics, Marks helped reveal how cancer cells arise. He developed new chemotherapy and chemoprevention agents, including suberoylanilide hydroxamic acid, which transformed the treatment of cutaneous T-cell lymphoma and is currently undergoing trials to treat an array of cancers.

Read full article in the HICCC Newsroom